NeuroMetrix, Inc. (NURO:NASDAQ) closed at $4.58 on February 10, 2026, unchanged on the day. The stock trades 3.2% below its 52-week high of $4.73 and 72.2% above its 52-week low of $2.66. NeuroMetrix, Inc. is part of the Health Care sector (Medical/Dental Instruments).
In 252 trading sessions since October 23, 2025, NURO closed higher on 0 days (0%). Its best day was October 23, 2025 (0.00%) and its worst was October 23, 2025 (0.00%). It never moved 10% or more in a single session.
NeuroMetrix, Inc., a medical device company, develops and markets products for the detection, diagnosis, and monitoring of peripheral nerve and spinal cord disorders. The company develops wearable neuro-stimulation therapeutic devices and point-of-care neuropathy diagnostic tests to address chronic health conditions, including chronic pain, sleep disorders, and diabetes. Its marketed products include Quell, a wearable device for relief of chronic intractable pain, such as nerve pain due to diabetes and lower back problems; the SENSUS pain therapy device, a prescription neurostimulation device based on transcutaneous electrical nerve stimulation for relief of chronic intractable pain; DPNCheck, a test used to evaluate systemic neuropathies, such as diabetic peripheral neuropathy; and ADVANCE NCS/EMG system, a platform for the performance of traditional nerve conduction studies. The company offers its products to consumers, patients, retail merchandisers, health care professionals, durable medical equipment suppliers, physicians, clinics, hospitals, managed care organizations, independent distributors, retail health businesses, endocrinologists, podiatrists, neurologists, and physica...
Find more stocks like NURO with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.